- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00084214
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
March 5, 2014 updated by: Synta Pharmaceuticals Corp.
A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Study Overview
Detailed Description
STA-4783 is a taxane potentiator, enhancing the effect of antitumor response of paclitaxel.
In an attempt to improve efficacy, paclitaxel is sometimes used in combination with other anticancer agents.
When paclitaxel is combined with other anticancer agents, although response rate is usually increased, side effects are usually increased as well.
There is an urgent need for agents that can enhance the antitumor effects of paclitaxel without further increasing undesirable side effects.
Study Type
Interventional
Enrollment
103
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Genesis Cancer Center
-
Little Rock, Arkansas, United States, 72205-7101
- Univ Of Arkansas/Arkansas Research Center
-
-
California
-
San Diego, California, United States, 92121
- Scripps Cancer Center
-
San Francisco, California, United States, 94109
- Northern California Melanoma Center
-
Santa Monica, California, United States, 90404
- Cancer Institute Medical Group, Inc
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- Anschutz Cancer Pavillion - Univ Of Colorado
-
-
Connecticut
-
Stamford, Connecticut, United States, 06902-3628
- Hematology Oncology P.C.
-
Waterbury, Connecticut, United States, 06708
- Medical Oncology and Hematology, P.C.
-
-
Georgia
-
Atlanta, Georgia, United States, 30322-1013
- Emory University - Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Research Institute Hawaii Pacific Health
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Ltd.
-
Park Ridge, Illinois, United States, 60068
- Oncology Specialists
-
-
Indiana
-
Bloomington, Indiana, United States, 47403
- Cancer Care Center of Southern Indiana
-
Goshen, Indiana, United States, 46527-0139
- Center For Cancer Care At Goshen Health
-
Iindianapolis, Indiana, United States, 46202
- Indiana Oncology Hematology Consultants
-
New Albany, Indiana, United States, 47150-6809
- Cancer Care Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- James Graham Brown Cancer Center - University Of Louisville
-
-
Maine
-
Scarborough, Maine, United States, 04074
- Maine Center for Cancer Medicine & Blood Disorders
-
-
Minnesota
-
Robbinsdale, Minnesota, United States, 55422
- Hubert H. Humphrey Cancer Center
-
-
Missouri
-
Columbia, Missouri, United States, 65203
- Ellis Fischels Cancer Center - Univ Of Missouri
-
St. Louis, Missouri, United States, 63131
- Mountainside Hospital, Suburban Surgical Associates
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Piedmont Oncology Specialists
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Odyssey Research and St. Alexius Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97213-2933
- Providence Cancer Center
-
-
Virginia
-
Danville, Virginia, United States, 24541-4155
- Danville Hematology & Oncology, Inc.
-
Portsmouth, Virginia, United States, 23707
- Office of James Stark, MD
-
Richmond, Virginia, United States, 23230
- Virginia Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-0001
- University of Wisconsin Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- M or F 18 or older with histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin
- ECOG performance status of greater than or equal to 2
- Measurable disease per RECIST criteria
- Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy regimens are allowed)
- At least 4 weeks have passed since last chemotherapy or immunotherapy
- At least 2 weeks have passed since last radiotherapy.
- Life expectancy of greater than 12 weeks
- Clinical lab values within protocol parameters
Exclusion Criteria:
- Female patients pregnant or lactating
- Female patients of childbearing potential not using or not willing to use effective contraception
- Presence of a second malignancy other than nonmelanoma skin cancer
- Presence of a clinically significant and uncontrolled infection
- Presence of clinically significant arrythmias
- Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol
- History of severe hypersensitivity reactions to taxanes
- Use of any investigational agents within 4 weeks prior to the first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Study Registration Dates
First Submitted
June 9, 2004
First Submitted That Met QC Criteria
June 9, 2004
First Posted (Estimate)
June 10, 2004
Study Record Updates
Last Update Posted (Estimate)
March 6, 2014
Last Update Submitted That Met QC Criteria
March 5, 2014
Last Verified
December 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- 4783-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium